Evaluation of effect of cilostazol on cerebral glucose metabolism in patients with amnestic mild cognitive impairment and preclinical Alzheimer's disease with lacunar infarction.

Evaluation of effect of cilostazol on cerebral glucose metabolism in patients with amnestic mild cognitive impairment and preclinical Alzheimer's disease with lacunar infarction. - Effect of cilostazol on cerebral glucose metabolism in preclinical Alzheimer's disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006599

Enrollment

Registered

2011-10-25

Start date

2012-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

amnestic mild cognitive impairment and preclinical Alzheimer&#39

Interventions

Cilostazol 100mg daily for 3 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: MMSE 24-30

Exclusion criteria

Exclusion criteria: other anti-dementia drugs

Design outcomes

Primary

Measure	Time frame
MMSE,WMS-R,FDG-PET	—

Countries

Japan

Contacts

Public ContactTsuneyoshi Ota

Juntendo University School of Medicine Department of Psychiatry

ota@juntendo.ac.jp03-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026

Evaluation of effect of cilostazol on cerebral glucose metabolism in patients with amnestic mild cognitive impairment and preclinical Alzheimer&#39;s disease with lacunar infarction.